COMPARATIVE STUDY TO SEE THE EFFECT OF INTRACAMERAL MYDRIATICS VERSUS TOPICAL MYDRIATICS IN PUPIL DILATATION FOR PHACOEMULSIFICATION CATARACT SURGERY

Traditional methods of achieving optimal pupil dilatation during phacoemulsification rely on topical mydriatics, such as tropicamide 0.8% and phenylephrine 5%. However, the emergence of intracameral mydriatics, specifically a fixed-dose combination (FDC) comprising tropicamide 0.2%, phenylephrine 2%, and preservative-free lidocaine 1%, presents a promising alternative. The existing literature acknowledges the advantages of intracameral mydriatics, including potentially faster onset, prolonged duration of action, and reduced dependence on patient compliance. However, the majority of studies and safety data primarily pertain to populations outside the Indian subcontinent. Given the unique characteristics of the Indian demographic, such as varied genetic predispositions and environmental factors, there is a compelling need to assess the safety and efficacy of intracameral mydriatics specifically within this population. This study aims to address this critical gap in knowledge by conducting a comprehensive comparative analysis of the effects of intracameral mydriatics versus topical mydriatics in achieving pupil dilatation for phacoemulsification cataract surgery. By meticulously evaluating parameters such as speed, extent, and sustainability of pupil dilation, as well as monitoring potential adverse events, the study seeks to provide valuable insights into the appropriateness of intracameral mydriatics within the Indian context. Ultimately, the findings are expected to inform clinical practice, optimize surgical outcomes, and contribute to the ongoing refinement of cataract surgery protocols in the pursuit of enhanced patient care.